Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U44 Clinical Trial Optional)
Grant Opportunity Analysis
The National Institutes of Health (NIH) has announced a funding opportunity titled "Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U44 Clinical Trial Optional)" aimed at supporting the clinical validation of candidate biomarkers for neurological diseases. This initiative seeks proposals from small businesses to demonstrate the clinical effectiveness of identified biomarkers, ensuring they meet FDA guidelines for validation, including establishing their clinical sensitivity and specificity. The funding opportunity allows for both Phase I and Phase II applications, with budget limits of up to $700,000 and $1,500,000, respectively, over a period of two to three years. Interested applicants should note that the application submission begins on February 22, 2024, and for further inquiries, they can contact NIH Grants Information at grantsinfo@nih.gov. More details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-24-096.html.
Eligible Applicants
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.